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        Innate immune responses play a critical role in 
defending the host from pathogens. Pathogen-
associated molecular patterns stimulate pattern 
recognition receptors such as the Toll-like re-
ceptors (TLRs), which activate a set of signal-
ing pathways, inducing expression of innate 
immune eff  ectors (  1  –  3  ). LPS is a pathogen-as-
sociated molecular pattern that interacts with 
TLR4, which in turn interacts with intracellu-
lar adaptor proteins such as MyD88 (  4  ). The 
TLR4 signaling complex then activates two in-
tracellular pathways, the NF-    B signaling path-
way and the mitogen-activated protein kinase 
(MAPK) cascade, both of which direct an in-
fl  ammatory response. 
  The MAPK pathway plays a critical role 
in innate immune signaling (  5, 6  ). The three 
major families of MAPKs include extracellu-
lar signal-regulated kinases (ERKs), the p38 
MAPKs, and the c-Jun NH2-terminal kinases 
(JNK) (  7  –  9  ). These MAPKs are activated by 
MAPK kinases (MAPKKs) (  10, 11  ). MAPKKs 
are in turn activated by a set of MAPKK kinases. 
The MAPK pathway that mediates innate im-
mune signaling includes MKK3/4/6, p38, and 
JNK (  12  –  14  ). 
  Negative regulators of innate immunity pre-
vent excessive infl  ammation and autoimmunity 
(  15, 16  ). Distinct inhibitors of TLR signaling 
have been identifi  ed, many of which act upon 
the Myd88 pathway (  3, 17  –  24  ). Furthermore, 
endogenous inhibitors of the MAPK system may 
also negatively regulate TLR signaling (  25  –  28  ). 
  MAPK phosphatases (MKPs) are dual-speci-
fi  city phosphatases that inactivate MAPK mem-
bers by dephosphorylating phosphotyrosine and 
phosphothreonine residues (  29  –  34  ). The MKP 
family includes four types; the type II, III, and 
IV MKPs all include a MAPK-docking domain 
and a dual-specifi  c phosphatase domain (  34  ). 
The docking domain mediates interactions be-
tween MKP and its substrate MAPK. MKP 
binding to its MAPK target via the docking do-
main increases MKP catalytic activity by more 
than fi  vefold (  35  –  38  ). MKP-1 can be phos-
phorylated to regulate its stability, but other 
modifi  cations have not been reported (  39  ). Re-
cent studies have emphasized the importance of 
MKP-1 in regulating innate immune responses. 
Mice lacking MKP-1 are more susceptible to 
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    The mitogen-activated protein kinase (MAPK) pathway plays a critical role in Toll-like 
receptor (TLR) signaling. MAPK phosphatase-1 (MKP-1) inhibits the MAPK pathway and 
decreases TLR signaling, but the regulation of MKP-1 is not completely understood. We 
now show that MKP-1 is acetylated, and that acetylation regulates its ability to interact 
with its substrates and deactivate infl  ammatory signaling. We found that LPS activates 
acetylation of MKP-1. MKP-1 is acetylated by p300 on lysine residue K57 within its sub-
strate-binding domain. Acetylation of MKP-1 enhances its interaction with p38, thereby 
increasing its phosphatase activity and interrupting MAPK signaling. Inhibition of deacety-
lases increases MKP-1 acetylation and blocks MAPK signaling in wild-type (WT) cells; 
however, deacetylase inhibitors have no effect in cells lacking MKP-1. Furthermore, histone 
deacetylase inhibitors reduce infl  ammation and mortality in WT mice treated with LPS, but 
fail to protect MKP-1 knockout mice. Our data suggest that acetylation of MKP-1 inhibits 
innate immune signaling. This pathway may be an important therapeutic target in the 
treatment of infl  ammatory diseases. 1492 ACETYLATION OF MKP-1 INHIBITS TLR SIGNALING   | Cao et al. 
do not regulate expression of infl  ammatory proteins only by a 
general eff  ect on transcription, but may also have specifi  c tar-
gets. In this study, we searched for acetylated targets in innate 
immune signaling, and we discovered that acetylation of MKP-1 
is a negative regulator of innate immunity. 
    RESULTS   
  HDAC inhibitors decrease LPS activation 
of NOS2 expression 
  To explore the eff  ect of global protein acetylation upon NOS2 
expression, we pretreated RAW 264.7 murine macrophages 
with the HDAC inhibitor trichostatin A (TSA) or control, 
LPS than WT mice (  28, 40  –  42  ). Furthermore, in response to 
TLR signals, macrophages lacking MKP-1 produce higher 
levels of proinfl  ammatory cytokines. 
  Histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) can regulate gene expression by modifying histone 
proteins (  43  –  45  ). However, HAT and HDAC can regulate 
specifi  c signaling pathways and have other targets in addition 
to histones, including NF-    B, Stat3, and p53 (  46  –  48  ). Recent 
reports suggest that inhibitors of HDAC can decrease infl  am-
mation (  49  –  56  ). Interestingly, HDAC inhibitors repress ex-
pression of some infl  ammatory genes, but increase expression 
of others (  57  ). This reinforces the idea that HDAC inhibitors 
    Figure 1.     Deacetylase inhibitors decrease LPS activation of NO synthesis and NOS2 expression.   (A) TSA inhibits LPS-induced NO production in a 
dose-dependent manner. RAW cells were pretreated with increasing amounts of TSA for 1 h, and then treated with or without LPS 100 ng/ml for 16 h, 
and the amount of NO  2        was measured in the supernatant by the Griess reaction. (  n   = 3   ±   the SD). (B) Sodium butyrate inhibits LPS-induced NO produc-
tion in RAW cells. RAW cells were pretreated with increasing amounts of sodium butyrate for 1 h and treated with or without LPS 100 ng/ml for 16 h, and 
the amount of NO  2        was measured in the supernatant by the Griess reaction (  n   = 3   ±   the SD). (C) TSA inhibits the LPS-induced increase in NOS2 RNA 
levels (dose  –  response). RAW cells were pretreated with increasing amounts of TSA for 1 h and treated with LPS 100 ng/ml for 6 h. Total RNA was analyzed 
by Northern blotting with a cDNA probe for NOS2 (top) or a ribosomal phosphoprotein RNA 36B4 as a control (bottom). (D) TSA inhibits LPS-induced 
increase in NOS2 RNA levels (time course). RAW cells were pretreated with TSA 30 ng/ml for 1 h and treated with LPS 100 ng/ml for 0  –  7 h. Total RNA was 
analyzed by Northern blotting with a cDNA probe for NOS2. (E) TSA inhibits LPS-induced increase in NOS2 protein levels (dose  –  response). RAW cells were 
pretreated with increasing amounts of TSA for 1 h, LPS was added for 6 h, and cell lysates were immunoblotted with antibody to NOS2 (top) or ER     (bot-
tom). (F) TSA decreases LPS-induced infl  ammatory cytokine RNA levels. RAW cells were treated with LPS and TSA for 4 h. Total RNA was analyzed by 
Northern blotting with probes for TNF-   ,  IL-1   , IL-6, or GAPDH as a control. (G) TSA decreases LPS-, PGN-, and poly(I:C)-induced NOS2 protein levels. 
RAW cells were treated with the TLR agonists PGN, poly(I:C), LPS, or   E. coli   for 16 h. Cell lysates were immunoblotted with antibody to NOS2. (H) TSA 
slightly increases expression of COX-2 and CXCL2. RAW cells were treated with LPS, TSA, or both as in F, and analyzed for COX-2 and CXCL2 expression 
by  RT-PCR.   JEM VOL. 205, June 9, 2008 
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alone, TSA alone, or LPS and TSA together to RAW cells, 
and then measured levels of the three major groups of phos-
phorylated MAPK proteins as follows: p38; ERK1 and ERK2; 
and JNK1 and JNK2. LPS increases phosphorylation of p38, 
ERK1/2, and JNK1/2 (  Fig. 2 B  ). TSA decreases LPS-in-
duced phosphorylation of p38 and ERK1/2, but not JNK1/2 
(  Fig. 2 B  ). 
  The p38 pathway of MAPK signaling includes MKK3/6, 
which phosphorylates p38, which in turn phosphorylates 
ELK-1 and other targets (  59  ). LPS increases phosphorylation 
of all components of this pathway, from MKK3/6 to p38 to 
Elk-1 (  Fig. 2 C  ). Although TSA decreases phosphorylation of 
p38 and Elk-1, TSA does not aff  ect phosphorylation of the 
upstream MAPKK MKK3/6 (  Fig. 2 C  ). Furthermore, TSA 
does not aff  ect MKK3 kinase activity (  Fig. 2 D  ). 
  These data suggest that HDAC inhibition acts upon the 
MAPK signaling pathway at the level of p38, possibly upon a 
kinase or phosphatase that modifi  es p38. Furthermore, our data 
imply that proteins that phosphorylate p38, such as MKK3/6 
or transforming growth factor       –  activated protein kinase 1, 
are not aff  ected by acetylation (  60  ). 
  Acetylation of MKP-1 
  We next determined which molecules in the MAPK signal 
pathway are acetylated, focusing on proteins that modify p38. 
We reasoned that acetylated MAPK components would in-
teract with acetylases. Accordingly, we immunoprecipitated 
the histone acetylase p300 from RAW cell lysates, and im-
munoblotted precipitants for a variety of MAPK proteins, in-
cluding MKP-1. We found that MKP-1 does not associate 
with p300 in resting macrophages (  Fig. 3 A  ).   However, we 
reasoned that HDAC and HAT might compete for the same 
acetylation site of MKP-1, and blockade of HDAC might 
permit an unopposed increase in the interaction between 
p300 and MKP-1. For example, TSA not only increases acet-
ylation of Sp1 but also recruits p300 into a complex that in-
cludes Sp1 and HDAC (  61  ). Accordingly, we tested the idea 
that TSA might increase the interaction of p300 and MKP-1. 
We found that MKP-1 associates with p300 in TSA-treated   
macrophages (  Fig. 3 A  ). 
  We then measured the acetylation of MKP-1 by immuno-
precipitating MKP-1 from RAW macrophages labeled with 
[  3  H]sodium acetate. MKP-1 is not acetylated in resting cells 
(  Fig. 3 B  ). However, LPS triggers acetylation of MKP-1. 
Furthermore, HDAC inhibition enhances acetylation of MKP-1, 
peaking 2 h after LPS and then decreasing (  Fig. 3 B  ). 
  Which lysine residues of MKP-1 are acetylated? MKP-1 
contains a lysine K57 that is conserved among most MKP 
isoforms (including MKP isoforms 1, 2, 3, and X;   Table I  ).   
This conserved lysine residue is located in the middle of the 
MKP-1 docking domain, which interacts with p38. We 
therefore explored whether or not this particular lysine resi-
due of MKP-1 is acetylated, using two complementary tech-
niques: radiolabeled cells and purifi  ed peptides (  47, 48  ). We 
synthesized a peptide consisting of MKP-1 residues 47  –  76, 
designated MKP-1(47  –  76)(WT). We also synthesized a mutant 
added LPS, and measured the concentration of the nitric 
oxide (NO) metabolite nitrite (NO  2         ) in the media. TSA 
decreases LPS-activated NO production in a dose-dependent 
manner (  Fig. 1 A  ).   Another HDAC inhibitor, sodium butyr-
ate, also inhibits NO production (  Fig. 1 B  ). To explore 
the mechanism by which TSA inhibits NO production, 
we measured the steady-state RNA and protein levels of 
NOS2 in LPS-stimulated macrophages. TSA decreases NOS2 
mRNA levels in a dose- and time-dependent manner (  Fig. 1, 
C and D  ). TSA also decreases NOS2 steady-state protein lev-
els (  Fig. 1 E  ). These results suggest that HDACs regulate 
NOS2 expression. 
  We also explored the eff  ect of TSA upon expression 
of infl  ammatory cytokines. TSA inhibits the expression of 
TNF-    , IL-6, and IL-1     in LPS-stimulated macrophages 
(  Fig. 1 F  ). We examined the eff  ect of TSA upon activa-
tion of other TLR signaling pathways. LPS or   Escherichia 
coli  , which are activators of TLR4 signaling, peptidoglycan, 
which is an activator of TLR2 signaling, or double-stranded 
RNA, which is an activator of TLR3 signaling, can activate 
NOS2 expression in macrophages (  Fig. 1 G  ). TSA inhibits 
expression of NOS2 activated by each of these four TLR 
activators (  Fig. 1 G  ). However, we found that TSA slightly 
increases the expression of other proinfl  ammatory molecules, 
such as COX-2 and CXCL2 (  Fig. 1 H   and Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20071728/DC1). 
These results suggest that HDACs regulate expression of a 
subset of proinfl  ammatory cytokines activated by multiple 
TLR activators (  56, 57  ). 
  HDAC inhibitors do not regulate NOS2 expression 
through NF-    B 
  To determine the mechanism by which HDAC inhibitors 
decrease NOS2 expression, we examined the eff  ect of TSA 
upon NF-    B, which is a transcriptional regulator of NOS2. 
However, TSA does not aff  ect LPS activation of the NF-
    B pathway. In fact, TSA slightly increases LPS-triggered 
I    B     degradation, p65 nuclear translocation,     B-binding 
activity, and NF-    B transactivation of the NOS2 promoter 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20071728/DC1). Although TSA slightly enhances NF-kB 
signaling, it also decreases NOS2 expression (  Fig. 1  ). We there-
fore explored the eff  ect of TSA upon other pathways that 
regulate NOS2 expression. 
  HDAC inhibitors inhibit MAPK pathway 
  Because the MAPK pathway regulates NOS2 expression 
(  58  ), we explored the eff  ect of HDAC inhibition upon the 
MAPK pathway. We treated RAW macrophages with 
SB203580 to inhibit p38, with U0126 to inhibit ERK, or 
with SP600125 to inhibit Jun-N-terminal kinase (JNK); we 
then added LPS and measured expression of NOS2 protein. 
MAPK inhibitors decrease LPS activation of NOS2 ex-
pression (  Fig. 2 A  ).   These MAPK inhibitors are not cyto-
toxic (unpublished data). To identify which MAPKs are 
aff  ected by deacetylase inhibition, we added media, LPS 1494 ACETYLATION OF MKP-1 INHIBITS TLR SIGNALING   | Cao et al. 
1(WT), or with an expression vector expressing an HA-
tagged mutant MKP-1 with a K57R substitution, designated 
HA-MKP-1(K57R). We then treated cells with LPS and 
TSA. We precipitated cell lysates with antibody to acetyl-
lysine and the precipitants were fractionated and immuno-
blotted with antibody to HA. MKP-1 is acetylated in response 
to LPS and TSA, but MKP-1(K57R) is not (  Fig. 3 D  ). 
peptide consisting of MKP-1(47  –  76) with an arginine sub-
stituted for lysine at residue 57, designated MKP-1(47  –
  76)(K57R). We incubated the WT and mutant MKP-1 
peptides with recombinant acetyltransferases p300 or PCAF 
(p300/CBP-associated factor) and [  14  C]acetyl-CoA. p300 acet-
ylates MKP-1(47  –  76) (  Fig. 3 C  ). However, p300 cannot 
acetylate MKP-1(47  –  76)(K57R) (  Fig. 3  ). Similar results were 
obtained for PCAF and the WT and mutant MKP-1 pep-
tides. These data suggest that these acetyltransferases acetylate 
MKP-1 on residue K57. 
  We next searched for acetylation of MKP-1 in cells. We 
transfected HEK293 cells with a vector expressing an HA tag 
fused to a fragment of WT MKP-1, designated HA-MKP-
    Figure 2.     Deacetylase inhibition blocks MAPK signaling.  (A)  The 
MAPK pathway regulates NOS2 expression. RAW cells were treated for 1 h 
with 10   μ  M of the p38 MAPK inhibitor SB203580, 10   μ  M of the MEK1/2 
inhibitor UO126, or 5   μ  M of the JNK inhibitor SP600125, and then 100 ng/
ml LPS was added for 6 h and cell lysates were immunoblotted with anti-
body to NOS2 (top) or MEK1/2 (bottom left) of HuR (bottom right). (B) TSA 
inhibits phosphorylation of the MAPKs p38 and ERK1, but not JNK. RAW 
cells were pretreated with 30 ng/ml TSA for 1 h, and then treated with 
100 ng/ml LPS for 30 min, and cell lysates were immunoblotted with anti-
bodies to MAPK pathway members. (C) TSA inhibits the MKK3/6  –  p38  –  Elk-
1 signaling cascade between MKK3/6 and p38. RAW cells were treated 
with TSA and LPS as in B, and cell lysates immunoblotted with antibodies 
to MAPK members. (D) TSA does not inhibit MKK3 kinase activity. RAW 
cells were treated with LPS and TSA as in B and C, and lysates were im-
munoprecipitated with antibody to MKK3. The kinase activity of MKK3 
was assayed by adding recombinant GST-p38 and ATP to immunoprecipi-
tated MKK3 for 30 min at 30  °  C, and then immunoblotting for phospho-
p38 (top) and total p38 (bottom).     
    Figure 3.     MKP-1 is acetylated.   (A) MKP-1 interacts with the histone 
acetyl transferase p300 in RAW cells. RAW cells were treated with TSA 
and LPS. Cell lysates were immunoprecipitated with antibody to p300, 
fractionated by SDS-PAGE, and immunoblotted with antibodies to MKP-1. 
Immunoblots of total MKP-1 and p300 are shown in the middle and bot-
tom gels. (B) TSA increases MKP-1 acetylation. RAW cells were pretreated 
with [  3  H]sodium acetate for 1 h and TSA for 0.5 h and with 100 ng/ml LPS 
for 0  –  3 h, and then cell lysates were immunoprecipitated with antibody 
to MKP-1 and autoradiographed (top) or immunoblotted with antibody to 
MKP-1 (bottom). (C) p300 and PCAF acetylate MKP-1 on residue K57 in 
vitro. A peptide encoding the MAPK docking domain of WT (WT) MKP-1 
(amino acids 47 to 76) was incubated with recombinant p300 HAT domain 
or recombinant PCAF in the presence of [  14  C]-acetyl CoA. A mutant MKP-
1 peptide with lysine replaced by arginine (K57R) was used as a control. 
The reactions were fractionated by 16.5% Tris-Tricine gel and autoradio-
graphed. (D) MKP-1 is acetylated on residue K57 in cells. HEK293 cells 
were transfected with vectors expressing a fragment of WT HA-MKP-
1(WT) or mutant HA-MKP-1(K57R), and then treated with TSA and LPS as 
above. Cell lysates were immunoprecipitated with antibody to acetyl-
lysine, fractionated by SDS-PAGE, and immunoblotted with antibody to 
HA (top). Total lysates were also immunoblotted for HA-MKP-1 (bottom).     JEM VOL. 205, June 9, 2008 
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  To explore the eff  ects of acetylation upon the direct 
interaction of MKP-1 and p38, we used recombinant poly-
peptides. We synthesized a biotinylated MKP-1 peptide, des-
ignated biotin-MKP-1(K57), and a similar peptide with an 
acetylated K57 residue, designated biotin-MKP-1(K57Ac). 
We incubated the WT and acetylated MKP-1 peptide with 
recombinant p38, precipitated the mixture with streptavi-
din  –  agarose beads, and immunoblotted precipitants with an-
tibody to p38. The MKP-1 peptide with an acetylated lysine 
in the docking site domain has a higher affi   nity for p38 than 
a nonacetylated MKP-1 peptide (  Fig. 4 B  ). 
  We further defi  ned the interaction between MKP-1 and 
p38 using surface plasmon resonance (SPR). Biotinylated 
MKP-1 peptide was immobilized to a streptavidin sensor 
chip, using either biotin-MKP-1(47  –  76) or biotin-MKP-
1(47-K57Ac-76). We injected recombinant (His)  6  -p38 into 
  These data suggest that MKP-1 is acetylated on residue 
K57 in vitro and in cells. 
  Acetylation of MKP-1 increases its interaction with p38 
  We next examined the eff  ect of MKP-1 acetylation upon its 
interaction with p38. We treated RAW cells with LPS and 
TSA, and then immunoprecipitated cell lysates with anti-
body to p38 and immunoblotted precipitants with antibody 
to MKP-1. HDAC inhibition increases the association be-
tween p38 and MKP-1 in cells (  Fig. 4 A  ).   Immunoprecipi-
tation using antibody to MKP-1 and immunoblotting for 
p38 confi  rm that p38 and MKP-1 form a complex within 
cells. It appears as if TSA alone increases the interaction be-
tween MKP-1 and p38, even in the absence of LPS (  Fig. 4 A  ). 
Furthermore, TSA increases the expression of MKP-1 lev-
els (  Fig. 4 A  ). 
    Figure 4.     MKP-1 acetylation increases the interaction between MKP-1 and p38.   (A) TSA increases MKP-1 interaction with p38 in cells. RAW cells 
were treated with LPS and TSA for 1 h, cell lysates were immunoprecipitated with antibodies to p38 or MKP-1, and immunoprecipitates were immuno-
blotted with antibodies as shown. (B) Acetylation increases MKP-1 peptide interaction with p38 in vitro. Biotinylated peptides from the MKP-1 docking 
domain (containing aa residues 46  –  74) were synthesized with lysine (K57) or with acetyl-lysine (K57Ac). MKP-1 peptides were incubated with recombi-
nant p38, precipitated with streptavidin  –  agarose beads, and precipitants were immunoblotted with antibody to p38. (top) p38 precipitant with MKP-1 
peptide. (bottom) Total p38 input. (C) Acetylation increases MKP-1 peptide interaction with p38 in vitro. Biotin-MKP-1(47  –  76) (blue) and biotin-MKP-
1(47-K57Ac-76) (red) were immobilized onto a streptavidin sensor chip. Recombinant p38 was injected into the fl  ow cell, and changes in SPR were mea-
sured over 15 min. This experiment was repeated twice with similar results. (D) Acetylation increases WT MKP-1(WT), but not mutant MKP-1(K57R), 
interaction with p38 in cells. HeLa cells were transfected with plasmids expressing MKP-1(WT)-ER     or  MKP-1(_K57R)-ER   . The cells were treated with 4-
HT to induce MKP-1-ER     expression, and then treated with LPS and TSA for 1 h. Cell lysates were immunoprecipitated and immunoblotted with antibodies 
to ER     and to p38 as indicated. (E) Acetylation increases WT MKP-1(WT) interaction with ERK, but not mutant MKP-1(K57R) interaction with ERK. 
HeLa cells were transfected with plasmids expressing MKP-1(WT)-ER     or  MKP-1(K57R)-ER    and  His 6  -ERK1. The cells were treated with 4-HT to induce 
MKP-1-ER     expression, and then treated with LPS and TSA for 1 h. Cell lysates were immunoprecipitated, and then immunoblotted with antibody to the 
ER     tag of MKP-1 and antibody to the (His)  6   tag of (His)  6 -ERK1.   1496 ACETYLATION OF MKP-1 INHIBITS TLR SIGNALING   | Cao et al. 
combinant MKP-1 was acetylated or not with p300 and 
acetyl-CoA, and then incubated with 3-O-methylfl  uores-
cein phosphate (OMFP) at 30  °  C, and the OD 477 nm was 
measured over 0  –  40 min. Acetylation of MKP-1 has a negli-
gible eff  ect on phosphatase activity (  Fig. 5 C  , closed circles 
vs. open circles). Recombinant p38 increases the phospha-
tase activity of MKP-1 (  Fig. 5 C  , open squares vs. open circles). 
This is expected because substrate binding to MKP-1 increases 
MKP-1 catalytic activity (  35  –  38  ). However, acetylation of 
the fl  ow cell and measured changes in SPR. Recombinant 
p38 associates with both peptides (  Fig. 4 C  ). However, the 
association rate constant for p38 with the acetylated MKP-1 
peptide is greater than for p38 with the unmodifi  ed MKP-1 
peptide (7.9   ×   10  3   vs. 4.0   ×   10  3   1/Ms); and the dissociation 
rate constant for p38 from the acetylated MKP-1 peptide is 
less than for p38 from the unmodifi  ed MKP-1 peptide (1.5   ×   
10      4   vs. 3.4   ×   10      4   1/s;   Fig. 4 C  ). Thus, the affi   nity constant 
between p38 and acetylated MKP-1 peptide is     4.5-fold 
greater than the affi   nity constant between p38 and unmodi-
fi  ed MKP-1 peptide. 
  To explore the importance of the K57 residue in mediating 
the interaction between MKP-1 and p38 in cells, we trans-
fected cells with an inducible vector expressing a fusion poly-
peptide consisting of the estrogen receptor      (ER    ) fused to 
WT MKP-1, designated MKP-1(WT)-ER    . Other cells were 
transfected with a vector expressing the mutant MKP-1(K57R)-
ER    . Cells were cotransfected with a vector expressing FLAG-
tagged p38 (FLAG-p38). Tamoxifen was added to cells to 
induce expression of MKP-1-ER    . Cells expressing both 
FLAG-p38 and MKP-1-ER     were treated with LPS and TSA, 
cell lysates were immunoprecipitated with antibody to ER    , 
and precipitants immunoblotted with antibody to FLAG. 
HDAC inhibition increases the interaction between MKP-
1(WT) and p38 (  Fig. 4 D  ). However, HDAC inhibition is not 
able to aff  ect the interaction between mutant MKP-1(K57R) 
and p38 (  Fig. 4 D  ). TSA also increases the interaction of ERK1 
and WT, but not mutant, MKP-1 in cells (  Fig. 4 E  ). 
  These data suggest that acetylation of the MKP-1 lysine 
residue 57 regulates the interaction between MKP-1 and p38. 
  Acetylation of MKP-1 decreases phosphorylation of p38 
  We predicted that by enhancing the interaction of MKP-1 
and p38, acetylation of MKP-1 would increase the dephos-
phorylation of p38. To test this hypothesis, we synthesized 
recombinant MKP-1(WT) and MKP-1(K57R) in vitro, 
added p300 to acetylate MKP-1, and then incubated the 
mixture with phospho-p38. The mixture was fractionated 
and then immunoblotted for phospho-p38. Recombinant 
MKP-1 reduces phosphorylation of p38 (  Fig. 5 A  , left).   Add-
ing the acetyltransferase p300 which acetylates MKP-1 leads 
to a further decrease in phosphorylation of p38 (  Fig. 5 A  , 
left). Although MKP-1(K57R) can decrease the phosphoryl-
ation of p38, addition of p300 has no further eff  ect on MKP-
1 dephosphorylation of p38 (  Fig. 5 A  , right). 
  We next examined the eff  ect of MKP-1 acetylation upon 
dephosphorylation of p38 inside cells. RAW cells were treated 
with LPS and TSA, and endogenous MKP-1 was immuno-
precipitated, and incubated with recombinant phospho-p38. 
HDAC inhibition enhances the ability of MKP-1 to remove 
phosphate groups from recombinant phospho-p38 (  Fig. 5 B  ). 
MKP-1 derived from TSA-treated cells also removes more 
phosphate from recombinant phospho-ERK1 than MKP-1 
from control cells (  Fig. 5 B  ). 
  To explore the eff  ect of acetylation upon MKP-1 phos-
phatase activity, we used an in vitro phosphatase assay. Re-
    Figure 5.     MKP-1 acetylation decreases phosphorylation of p38. 
  (A) Recombinant MKP-1. Recombinant MKP-1 was treated with p300 or 
control, incubated with recombinant phospho-p38, and levels of phos-
pho-p38 were measured by immunoblotting. (B) MKP-1 derived from 
cells. RAW cells were treated with LPS and TSA or control for 4 h, and cell 
lysates were immunoprecipitated with antibody to MKP-1. Immunopre-
cipitates were incubated with recombinant phospho-p38 or phospho-
ERK1, and then immunoblotted with antibodies to phospho-p38 or 
phospho-ERK. The total amount of phospho-p38 or phospho-ERK1 added 
to the reaction is shown as input above. (C) MKP-1 catalytic assay. Re-
combinant MKP-1 was pretreated or not with p300 and acetyl-CoA for 
30 min at 30  °  C, and then recombinant p38 or control was added for 1 h 
at 30  °  C. The artifi  cial substrate OMFP was added and the A 477 nm was 
measured at 30  °  C for 0  –  40 min (  n   = 2   ±   the SD; error bars too small 
to  see).   JEM VOL. 205, June 9, 2008 
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MKP-1 increases the phosphatase activity of MKP-1 in the 
presence of p38 by     125% (  Fig. 5 C  , closed vs. open squares). 
  These data suggest that acetylation of MKP-1 does not 
directly change its phosphatase activity. However, acetylation 
of MKP-1 indirectly increases its activity, by increasing its af-
fi  nity for its substrate. 
  MKP-1 mediates the effects of acetylation upon 
MAPK signaling 
  To demonstrate the importance of MKP-1 in deacetylase 
regulation of MAPK signaling, we followed two complemen-
tary strategies. We fi  rst used RNA silencing (small interfering 
[si]RNA) to decrease expression of MKP-1 in macrophages. 
RAW cells were stably transfected with three diff  erent vec-
tors encoding siRNA hairpin sequences directed against 
MKP-1 nucleotides 67  –  85 (  Fig. 6 A  , clone #1) or MKP-1 
nucleotides 743  –  761 (clones #2 and #3) or a control siRNA 
sequence.    Four separate stably transfected clones were iso-
lated, and cell lysates were immunoblotted with antibody to 
MKP-1. The vector encoding siRNA against MKP-1 nucle-
otides 743  –  761 decreases MKP-1 expression (  Fig. 6 A  , clone 
#2 and #3). We then tested the eff  ect of knocking down 
MKP-1 expression upon the ability of HDAC inhibitors to 
regulate phosphorylation of p38 and expression of NOS2. In 
control cells expressing a control hairpin RNA, LPS increases 
phosphorylation of p38, and TSA limits this increase as be-
fore (  Fig. 6 B  ). However, siRNA of MKP-1 blocks the eff  ect 
of TSA (  Fig. 6 B  ). Additionally, TSA decreases LPS-induced 
NOS2 expression in control cells, but not in cells with de-
creased MKP-1 (  Fig. 6 B  ). 
  We next used cells derived from MKP-1      /      mice to 
show that acetylation regulates MKP-1 dephosphorylation 
of p38. Murine embryonic fi  broblasts (MEFs) from MKP-
1      /      mice and from MKP-1  +/      mice were treated with LPS 
and TSA, and phosphorylation of p38 was measured by 
immunoblotting. Inhibition of deacetylation decreases phos-
pho-p38 levels in heterozygous cells, but not in MKP-1 KO 
cells (  Fig. 6 C  ). 
  Can MKP-1 rescue the MKP-1 KO cells and restore sen-
sitivity to TSA? We transfected MEF cells from MKP-1      /      
mice with a vector expressing MKP-1(WT) or MKP-1(K57R). 
Cells were then treated with LPS and TSA, and levels of 
phospho-p38 were measured. Expression of ectopic MKP-
1(WT) restores the ability of TSA to decrease phospho-p38 
levels (  Fig. 6 D  , lane 3 and 4). However, expression of ecto-
pic MKP-1(K57R) cannot restore the eff  ects of TSA upon 
phospho-p38 (  Fig. 6 D  , lanes 7 and 8). Furthermore, ectopic 
expression of MKP-1(WT) in MEFs from MKP-1      /      mice 
also restores the ability of TSA to decrease LPS-induced 
TNF-     (  Fig. 6 E  ). 
  Finally, we explored the eff  ect of TSA upon primary mac-
rophages. We isolated primary macrophages by peritoneal la-
vage of resting WT or MKP-1 KO mice (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20071728/DC1). 
We then simulated the primary macrophages with TSA, LPS, 
or both, and measured phosphorylated p38. LPS induces 
    Figure 6.     MKP-1 mediates the effects of acetylation upon 
phosphorylation of p38 and NOS2 expression in cells.  (A)  MKP-1 
siRNA decreases MKP-1 expression in RAW cell lines. RAW cells were 
stably transfected with a vector encoding an siRNA hairpin sequences 
directed against MKP-1 nucleotides 67  –  85 (clone #1) or MKP-1 nucle-
otides 743  –  761 (clones #2-3) or a control siRNA sequence. Three 
separate stably transfected clones were isolated, and cell lysates 
were immunoblotted with antibody to MKP-1. (B) Knockdown of 
MKP-1 restores phospho-p38 levels and NOS2 expression in RAW cells 
treated with TSA. RAW cells stably transfected with siRNA directed 
against MKP-1 were treated with LPS and TSA, and cell lysates were 
immunoblotted with antibodies to NOS2 or MAPK family members. 
(C) Cells from MKP-1     /     mice maintain levels of phospho-p38 after 
treatment with TSA. MEFs from MKP-1     /+   or  MKP-1    /     mice  were 
treated with LPS and TSA for 30 min, and cell lysates were immuno-
blotted with antibodies to p38 as above. (D) Effects of TSA on p38 are 
restored by rescue of MKP-1     /     cells with MKP-1(WT), but not with 
MKP-1(K57R). Cells from MKP-1     /     were immortalized with SV40 
T-antigen, and then transfected with plasmids expressing MKP-1(WT)-ER    
or MKP-1(K57R)-ER    . The cells were treated with 4-HT to induce 
MKP-1-ER     expression, and then treated with LPS and TSA for 1 h. 
Cell lysates were immunoblotted with antibody to phospho-p38 (top), 
total p38 (middle), and the ER tag of MKP-1 (bottom). (E) Antiinflam-
matory effects of TSA are restored by rescue of MKP-1     /     cells  with 
MKP-1(WT), but not with MKP-1(K57R). Cells from MKP-1     /     were 
transfected with plasmids expressing MKP-1(WT)-ER     or  MKP-
1(K57R)-ER    , treated with 4-HT, and then treated with LPS and TSA 
for 1 h. Total cell RNA was analyzed by RT-PCR for IL-6, TNF-   ,  and 
GAPDH. (F) MKP-1 mediates TSA inhibition of p38 in primary 
macrophages. Peritoneal macrophages were isolated from WT 
and MKP-1     /     mice, stimulated with LPS, TSA, or both, as above, 
and cell lysates were immunoblotted with antibody to total or phos-
phorylated p38.     1498 ACETYLATION OF MKP-1 INHIBITS TLR SIGNALING   | Cao et al. 
  Collectively, these complementary data from the siRNA 
experiments and from the MKP-1 KO cells and from the 
MKP-1      /      primary macrophages all suggest that MKP-1 
mediates the eff  ects of acetylation upon p38. 
phospho-p38 in WT macrophages and higher levels of phos-
pho-p38 in MKP-1      /      macrophages (  Fig. 6 F  ). However, 
TSA only suppresses phospho-p38 in macrophages from WT 
mice, not in macrophages from MKP-1      /      mice. 
    Figure 7.     HDAC inhibition decreases LPS induced mortality and infl  ammation in mice.   (A) Mortality. Mice were injected with 1 mg/kg TSA daily 
for 5 d starting on day     2, injected with 50 mg/kg LPS on day 0, and their mortality was recorded each day after LPS treatment (  n   = 5; P   <   0.00001 for 
LPS vs. LPS with TSA). (B) TSA decreases LPS-induced liver infl  ammation. Mice were injected with saline (control) or TSA each day starting on day    2, 
injected with LPS on day 0, and livers were harvested 2 h (top) or 2 d (bottom) after LPS, sectioned, and stained with hematoxylin and eosin. (C) TSA de-
creases cytokine levels in serum. WT and MKP-1     /     mice were injected with TSA each day starting on day     2 and injected with LPS on day 0, and serum 
was collected 2 h after LPS treatment and analyzed by ELISA for TNF-     and  IL-1    ( n   = 2   ±   the SD; *, P   <   0.05   ±   the SD). (D) Cytokine from primary mac-
rophages. Macrophages were prepared from WT and MKP-1     /     mice, stimulated with TSA, LPS, or both, and after 4 h TNF-     and  IL-1    levels measured in 
the media by ELISA (  n   = 2   ±   SD). (E) TSA suppresses cytokine RNA in vivo. Mice were injected with TSA each day starting on day     2, injected with LPS on 
day 0, and liver RNA was harvested 4 h after LPS treatment and analyzed by RT-PCR for TNF-     and  IL-1   . Data are shown for two representative mice. 
(F) TSA slightly increases COX-2 and CXCL2 in vivo. Mice were injected with TSA and LPS as above, and liver RNA was harvested 4 h after LPS treatment 
and analyzed by RT-PCR for COX-2 and CXCL2 (  n   = 2). (G) Mouse NOS2 protein expression in liver. Mice were pretreated with increasing amounts of TSA 
for 4 h, and then treated with LPS for 16 h. Liver was harvested and immunoblotted with antibodies to NOS2 and MEK1. (H) MKP-1 is acetylated in mice. 
Mice were pretreated with TSA for 4 h, and then treated with LPS for 16 h as above. Liver lysates were immunoprecipitated with antibody to MKP-1 and 
immunoblotted with antibody to Ac-Lys or MKP-1. (I) MKP-1 mediates the protective effects of TSA after LPS. MKP-1 KO mice and their WT littermate 
controls were pretreated with TSA as above, and then injected with LPS 20 mg/kg, and their mortality was recorded (  n   = 5; P = 0.17 for LPS vs. LPS with TSA). 
(J) Proposed schematic of MKP-1 acetylation and regulation of innate immune signaling.     JEM VOL. 205, June 9, 2008 
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    DISCUSSION   
  Summary 
  The major fi  nding of this study is that acetylation of MKP-1 
regulates TLR signaling. Acetylation of MKP-1 increases its 
interaction with p38. A greater interaction of acetylated MKP-1 
with p38 increases MKP-1 phosphatase activity by   >  100%, 
decreases cellular phospho-p38 levels, and inhibits the MAPK 
signaling cascade. Acetylation may be a negative regulator of 
innate immune pathways (  Fig. 7 J  ). 
  Acetylation of MKP-1 
  Several lines of evidence suggest that MKP-1 is acetylated. 
The acetyltransferase p300 associates with MKP-1 in cells, 
and PCAF and p300 acetylate MKP-1 in vitro (  Fig. 3  ). Treat-
ment with the deacetylase inhibitor TSA increases levels of 
acetylated MKP-1 in cells and in mice (  Figs. 3 and 7  ). Previ-
ous studies have demonstrated that regulators of transcription 
are acetylated, including histones, transcription factors, nu-
clear import factors, and tubulin (  46  –  48, 62  –  66  ). Our data 
identify a member of a signal transduction cascades as a novel 
target of acetylation. 
  Acetylation of MKP-1 regulates protein  –  protein 
interactions and phosphatase activity 
  Our data suggest that acetylation of MKP-1 at a specifi  c site 
regulates its ability to interact with its substrates. The interac-
tion between MKP and their MAPK substrates is mediated 
by a docking domain in the N terminus of MKP and a dock-
ing domain in the MAPK substrate. The docking domain of 
murine MKP-1 extends from amino acid residues R47 to 
E63, and contains a central region with 4 arginine and 1 ly-
sine residues: RFSTIVRRRAKGAMGLE (  Table I  ) (  35, 67  ). 
We identifi  ed K57 as an amino acid residue acetylated in 
MKP-1 (  Figs. 3 and 4  ). This lysine residue lies within the 
docking domain of MKP-1. Acetylation of K57 may neutral-
ize the positive charge within the docking domain, which 
may explain our observation that acetylation of MAPK K57 
increases the interactions between MKP-1 and p38. Our data 
  HDAC inhibition decreases infl  ammation and mortality 
in mice exposed to LPS 
  To explore the in vivo relevance of MKP-1 acetylation, we 
used a murine model of septic shock (Fig. S4 A, available at 
http://www.jem.org/cgi/content/full/jem.20071728/DC1). 
We pretreated WT mice with an i.p. injection of 1 mg/kg 
TSA each day for 2 d, and then injected the mice with a sin-
gle i.p. dose of 50 mg/kg LPS. TSA was given for another 
3 d. LPS causes 100% mortality within 3 d (  Fig. 7 A  ).   How-
ever, TSA decreases the mortality of mice injected with LPS 
(  Fig. 7 A  ). Furthermore, TSA decreases mortality after LPS 
in a dose-responsive manner (Fig. S4 B). 
  We then analyzed the eff  ect of TSA upon infl  ammation. 
LPS treatment activates leukocyte infi  ltration into the liver 
within 2 h, but TSA treatment decreases LPS-induced in-
fl  ammation (  Fig. 7 B  , top). TSA also limits LPS-induced he-
patocyte edema and necrosis (  Fig. 7 B  , bottom). TSA also 
decreases levels of some cytokines in vivo. For example, TSA 
decreases serum levels of TNF-     and IL-1     in mice; and 
TSA suppresses these cytokines more in WT mice than in 
MKP-1      /      mice (  Fig. 7 C   and Fig. S5, available at http://
www.jem.org/cgi/content/full/jem.20071728/DC1). TSA 
decreases TNF-     by 62% in WT mice, but only by 22% in 
MKP-1      /      mice (  Fig. 7 C   left). TSA decreases IL-1     by 79% 
in WT mice, but only by 21% in MKP-1      /      mice (  Fig. 7 C   
right). TSA also suppresses cytokine production more in pri-
mary macrophages from WT mice than from MKP-1      /      
mice; in particular, TSA suppresses TNF-     by 87% in WT 
macrophages, but only by 27% in MKP-1      /      macrophages; 
and TSA decreases IL-1     by 85% in WT macrophages, but 
only by 34% in MKP-1 KO macrophages (  Fig. 7 D  ). Sup-
porting these data, TSA decreases LPS-induced TNF-     and 
IL-1     mRNA levels in the liver (  Fig. 7 E  ), and TSA de-
creases NOS2 steady-state protein levels in liver (  Fig. 7 G  ). 
However, TSA slightly increases COX-2 and CXCL2 ex-
pression in vivo (  Fig. 7 F  ). 
  We hypothesize that MKP-1 mediates part of the antiin-
fl  ammatory eff  ects of HDAC inhibitors. Immunoprecipita-
tion confi  rmed that MKP-1 is acetylated in livers of mice 
treated with LPS, and that TSA increases acetylation of MKP-
1 in vivo (  Fig. 7 H  ). We pretreated MKP-1 KO mice with 
TSA or control, and then injected them with 20 mg/kg LPS. 
LPS causes 100% mortality of MKP-1 KO mice within 3 d 
(  Fig. 7 I  ). However, TSA has a minimal and insignifi  cant ef-
fect on mortality (  Fig. 7 I  ). Thus, TSA protects WT mice 
from LPS (  Fig. 7 A  ), but TSA does not protect MKP-1 KO 
mice from LPS (  Fig. 7 I  ). 
  These data confi  rm the fi  ndings of others that LPS in-
duces higher levels of infl  ammation in MKP-1 KO mice 
compared with WT mice. Our data also confi  rm prior stud-
ies showing that HDAC inhibitors decrease infl  ammation 
caused by LPS in vivo. Furthermore, our data extend these 
studies by showing that TSA inhibits infl  ammation less in 
mice lacking MKP-1 than in WT mice. Therefore our data 
suggest that MKP-1 mediates part of the antiinfl  ammatory 
eff  ects of HDAC inhibitors in vivo. 
    Table I.       Docking domains of murine MKP isoforms 
MKP isoform Docking domain
MKP-1/DUSP1(m) RFSTIV  RR  RA  K  GAMGLE
MKP-1/DUSP1(h) RFSTIV  RR  RA  K  GAKGAG
MKP-2/DUSP4/HVH2 RCNTIV  RR  RA  K  GSVSLE
MKP-X/DUSP7 IPGLML  RR  LR  K  GNLPIR
MKP-3/DUSP6 IPGIML  RR  LQ  K  GNLPVR
MKP-5/DUSP10 ADKISR  RR  LQQG  K  ITVL
MKP-7/DUSP16 CSKLMK  RR  LQQD  K  VLIT
DUSP8/VH5 CSKLVK  RR  LQQG  K  VTIA
MKP-4/DUSP9 LPSLML  RR  LRRGSMSVR
DUSP2/PAC1 WNALLR  RR  ARGTPAAAL
DUSP2/PAC1 WNALLR  RR  ARGTPAAAL
The murine isoform of MKP-1 is designated by (m), the human isoform by (h). All 
other isoforms are murine. A di-arginine motif is shown in bold, and the adjacent 
lysine is italicized.1500 ACETYLATION OF MKP-1 INHIBITS TLR SIGNALING   | Cao et al. 
MKK3 were purchased from Cell Signaling Technology. Antibody to HA 
tag (5C12) was purchased from Roche. Antibodies to (His)  6   and FLAG tag 
were purchased from Sigma-Aldrich. Antibody to acetyl-histone was pur-
chased from Millipore. The MTS assay was purchased from Promega. 
  The mouse MKP-1 expression plasmids pUSEHA-MKP-1 (WT) and 
pUSEHA-MKP-1(K57R) were generated from a mouse MKP-1 cDNA (a 
gift from N.K. Tonks, Cold Spring Harbor Laboratory, Cold Spring Harbor, 
NY). The human MKP-1 expression vector was a gift from P. Stork (Ore-
gon Health Sciences University, Portland, OR). The bacterial expression 
vector for MKP-1 was a gift from S. Keyse (University of Dundee, Dundee, 
Scotland). The MKP-1(K57R) mutant was generated by PCR. The plasmid 
pCMV5 His  6  -ERK1 was a gift from P. Shaw (Queen  ’  s Medical Center, 
Nottingham, UK). The plasmid pcDNA Flag-p38 was a gift from J. Han 
(The Scripps Institute, San Diego, CA). We produced a plasmid vector 
to express MKP-1 under the control of estrogen. We cloned the MKP-1 
cDNA and cloned it into the expression vector pBABE-PURO such that it 
encodes a fusion polypeptide consisting of ER     ligand-binding domain 
fused to the MKP-1 (  72, 73  ). The addition of hydroxytamoxifen increases 
expression of the fusion protein. 
  Cell culture and transfection.     The mouse monocyte cell line RAW 264.7 
(American Type Culture Collection: TIB-71), HeLa cells, HEK 293 cells, or 
MEFs from MKP KO mice (provided by R.P. Ryseck, Bristol-Myers Squibb, 
Princeton, NJ) were grown in DME supplemented with 10% FBS and penicil-
lin/streptomycin. The cells were transfected with Lipofectamine 2000 follow-
ing the manufacturer  ’  s instructions (Invitrogen). Expression of the MKP-1-ER 
fusion protein was induced with 200 nM of 4-hydroxyl-tamoxifen (Sigma-
Aldrich). We prepared primary macrophages from resting mice (not treated 
with thioglycolate) by peritoneal lavage with 5 ml PBS. 
  In vitro kinase assay.     RAW cell lysates were immunoprecipitated with 
antibody to MKK3 (Cell Signaling Technology). The immunoprecipitates 
were washed and immunoblotted with antibody to phospho-p38. 
  Protein acetylation assay.     HeLa cells were transfected with plasmids 
pUSEHA-MKP-1(WT) or pUSEHA-MKP-1(K57R) for 16 h, incubated 
with 1 mCi/ml [  3  H]sodium acetate (ICN) for 1 h before addition of LPS and/
or TSA. Cells were lysed, immunoprecipitated with antibody to MKP-1 or 
antibody to HA-tag, fractionated by SDS PAGE, and autoradiographed. 
  MKP-1 peptides (docking domain) representing MKP-1 aa 47  –  76 
RFSTIVRRRAKGAMGLEHIVPNAELRGRLLA and a mutated peptide 
(K57R) RFSTIVRRRARGAMGLEHIVPNAELRGRLLA (Johns Hop-
kins DNA Core Facility) were incubated with recombinant p300 (HAT do-
main) or recombinant PCAF (Millipore) and 0.2 mM [  3  H]acetyl-CoA (ICN) 
at 30  °  C for 10 min, fractionated, and autoradiographed. 
  MKP-1 phosphatase assay.     For the in vitro MKP-1 phosphatase assay us-
ing phospho-p38 as a substrate, WT and mutant K57R MKP-1 proteins 
were generated from the plasmids pRSET-His-MKP-1 using an in vitro 
transcription and translation kit following the manufacturer  ’  s recommenda-
tion (TNT System; Promega). In vitro acetylation of MKP-1 was performed 
with recombinant p300 (Millipore) and cold acetyl-CoA (Sigma-Aldrich), as 
described in the previous section. 
  For the in vitro MKP-1 phosphatase assay using an artifi  cial substrate, 
acetylation of MKP-1 was performed by mixing recombinant MKP-1 0.66 
  μ  g, recombinant p300 2.5   μ  g, and 5   μ  l of 1 mM acetyl-CoA for 30 min at 
30  °  C. 2   μ  g of recombinant p38 was added, and the mixture was incubated 
for 1 h at 30  °  C. The artifi  cial substrate OMFP (Sigma-Aldrich) was added, 
and the A 477 nm was monitored at 30  °  C for 0  –  60 min. 
  MKP-1 peptide/p38 binding assay.     MKP-1 peptides encoding the MKP-1 
docking site aa residues 47  –  76 and conjugated to an N-terminal biotin (biotin-
RFSTIVRRRAKGAMGLE, designated MKP-1[47  –  76] and biotin-RFSTI-
VRRRAKacGAMGLE, designated MKP-1[47-K57Ac-76]), were incubated 
with 10   μ  M recombinant p38 for 2 h at 22  °  C, and then streptavidin agarose 
thus confi  rm other studies that found that acetylation of ly-
sine residues can increase protein  –  protein interactions (  47, 
68  ). The docking domains of all MKP family members are 
rich in arginine and lysine residues (  Table I  ). Some isoforms 
contain a lysine residue in the same relative position as MKP-
1 K57, others contain a lysine residue two amino acyl resi-
dues adjacent to K57 (  Table I  ). Other MKP isoforms lack a 
lysine in the docking domain. It is possible that selective MKP 
isoforms are acetylated in their respective docking domains, 
and others are not. 
  We also found that acetylation of MKP-1 indirectly af-
fects its phosphatase activity. Substrate binding to MKP-1 in-
creases the phosphatase activity (  35  ). Other MKP isoforms 
are also activated by interacting with their respective substrates 
(  69, 70  ). Our studies of recombinant MKP-1 show that acet-
ylation does not aff  ect phosphatase activity of the enzyme 
alone (  Fig. 5 C  .) However, acetylation of MKP-1 signifi  -
cantly increases phosphatase activity in the presence of sub-
strate by     125% (  Fig. 5 C  ). Our SPR assay of the interaction 
between p38 and MKP-1 peptides also suggests that acetyla-
tion of MKP-1 increases its affi   nity for its substrate (  Fig. 4 C  ). 
Collectively, our fi  ndings suggest that acetylation indirectly 
increases phosphatase activity by increasing the avidity of 
MKP-1 for its substrate. 
  Acetylation of MKP-1 negatively regulates innate 
immune signaling 
  Our data provide a mechanistic explanation for the antiin-
fl  ammatory eff  ects of HDAC inhibitors administered to ani-
mals. Numerous studies have shown that HDAC inhibitors 
decrease infl  ammation in vivo ( 50  –  55  ). Although it is thought 
that HDAC inhibitors decrease infl  ammation by regulating 
histone acetylation and infl  ammatory gene transcription, our 
data suggest that HDAC inhibitors decrease infl  ammation in 
part by increasing acetylation of MKP-1. However, HDAC 
inhibitors probably have other antiinfl   ammatory targets in 
addition to MKP-1, especially because TSA partially decreases 
cytokines in macrophages (  Fig. 7 D  ) and mice (  Fig. 7 C  ), and 
because TSA has a small protective eff   ect on MKP-1      /      
mouse mortality (  Fig. 7 I  ). Other studies suggest that MKP 
isoforms can be regulated by other posttranslational modifi  -
cations, such as oxidation of cysteine residues (  33, 71  ). Our 
data demonstrate another mechanism of regulating infl  am-
mation through MKP. Acetylation of target proteins in in-
fl  ammatory signaling pathways may be novel therapeutic 
targets in patients with sepsis or autoimmune diseases. 
    MATERIALS AND METHODS   
  Materials.     LPS, TSA, sodium butyrate, actinomycin D, and 4-hydroxy-
tamoxifen were purchased from Sigma-Aldrich. Peptidoglycan was pur-
chased from Fluka. Poly(I:C) was purchased from GE Healthcare. MAPK 
pathway inhibitor SB203580 (p38) and U0126 (ERK) were purchased from 
Calbiochem.   E. coli   DH5 was purchased from Invitrogen. Antibodies to NF-
    B p65, I    B    , NOS2 (M-19), MKP-1 (V-15), MEK1/2, pan acetyl-K 
(C2), p300 (C20), Elk-1, and ER     were purchased from Santa Cruz Bio-
technology, Inc. Antibodies to ERK1/2, phospho-ERK1/2, phospho-
MEK1/2, phospho-Raf, phospho-Elk-1, phospho-p90, p38, phospho-p38, 
JNK, phospho-JNK, phospho-Raf and acetyl-K, phospho-MKK3/6, and JEM VOL. 205, June 9, 2008 
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beads (Stratagene) were added for 16 h at 4  °  C. The beads were washed, eluted, 
and precipitants were analyzed by immunoblotting. 
  SPR was performed using a BIACORE 2000 (Biacore AB) with a sen-
sor chip preimmobilized with streptavidin (Sensor Chip SA; Biacore AB). 
The streptavidin sensor chip was loaded either with biotin-MKP-1(47  –  76) 
or with biotin-MKP-1(47-K57Ac-76; 150   μ  g in 100   μ  l PBS). Recombinant 
(His)  6  -p38 at 3.0   μ  M were injected over 6 min at a rate of 10   μ  l/min into 
fl  ow cells, and the SPR angle was measured and reported in resonance units. 
Association and disassociation rates were calculated. 
  Northern and Southern blotting.     Total cellular RNA was prepared from 
RAW cells treated with or without LPS and TSA using TRIZOL (Invitro-
gen). 20   μ  g of RNA was separated and transferred to a NYTRAN mem-
brane (Nytran; Schleicher   &   Schuell). Northern and Southern blot analysis 
was then performed, as previously described (  73  ). 
  Animal studies.     C57BL6/J male 4  –  6-wk-old mice were purchased from 
The Jackson Laboratory and housed at The Johns Hopkins University School 
of Medicine animal care facilities. All animal studies were performed under 
protocols approved by The Johns Hopkins University School of Medicine 
Animal Care and Use Committee. TSA was injected i.p. twice a day for a 
total of 5 d. A single dose of LPS (50   μ  g/gram body weight) was injected 
i.p. on day 3 for the WT mice on the C57BL/6J background; these doses of 
LPS were determined to kill 100% of the mice by day 2 (unpublished data). 
Mouse sera were tested by ELISA for levels of TNF-     and IL-1     (R  &  D 
Systems). Because the background of the original MKP-1 KO mice is not 
well defi  ned, we bred the MKP-1 KO mice (The Jackson Laboratory) onto 
a C57BL/6J background, and then interbred the heterozygotes for use as 
WT controls and MKP-1 KO mice. 
  Online supplemental materials.     Fig. S1 shows the eff  ect of TSA on 
COX-2. Fig. S2 shows that TSA does not aff  ect the NF-    B pathway. Fig. 
S3 characterizes the MKP-1 KO mice. Fig. S4 shows that TSA only al-
ters the mortality after LPS of WT mice, not of MKP-1 KO mice. Fig. 
S5 shows that TSA decreases infl  ammation only in WT mice, not MKP-1 
KO mice. The online version of this article is available at http://www.jem
.org/cgi/content/full/jem.20071728/DC1. 
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